骨髓间充质干细胞抗肝纤维化的研究进展  

Progress in Researches of Mesenchymal Stem Cells for Anti-liver Fibrosis

作　　者：林建辉[1] 陈怡[1] 李芹[1] 刘豫瑞[2] 

机构地区：[1]福建医科大学孟超肝胆医院肝内科,福建福州350001 [2]福建医科大学附属第一医院肝病中心,福建福州350005

出　　处：《现代生物医学进展》2016年第17期3398-3400,共3页Progress in Modern Biomedicine

基　　金：福州市科学技术局基金项目(2014-S-139-10);国家十二五重大专项子课题(2013ZX10005002-001-002)

摘　　要：肝纤维化及其终末病变肝硬化已严重危害全球人类健康,虽然慢性肝病的治疗手段和抗肝纤维化药物的研究已取得了很大进展,肝移植依然是最有效的治疗方案,但器官的紧缺却是一个现实问题。目前寻找有效的干预手段进行抗肝纤维化治疗已越来越受到大家的关注。近些年,大量基础及临床研究均证实在一定条件下利用骨髓间充质干细胞(MSCs)可以抑制肝星状细胞活化诱导其凋亡,实现肝纤维化逆转。随着干细胞技术的快速发展,基于骨髓间充质干细胞(MSCs)的细胞疗法在肝纤维化治疗领域的研究与应用已成为一个充满生命力的新方向。本文将对肝纤维化及基于MSCs的治疗机制进展及其应用进行综述。Liver fibrosis and its end stage cirrhosis are quite serious throughout the whole world. So far we have made breakthroughs in chronic liver diseases and anti-fibrosis but orthotopic liver transplantation is always the most effective therapy. However organ shortage is a reality. There has been increasing attention on finding the most appropriate way on anti-fibrosis nowadays. In recent years plenty of basic and clinical researches have been done identifying that cell- based therapy using mesenchymal stem cells（MSCs）may inhibit the proliferative, fibrogenic function and apoptosis of activated HSCs reversaling hepatic fibrosis. With the development of stem cells, the therapy based on MSCs may represent an attractive therapeutic option. Therefore, this article is mainly about liver fibrosis the mechanisms and the appliance on the therapy based o on MSCs.

关 键 词：肝细胞纤维化 骨髓间充质干细胞 细胞治疗 骨髓干细胞动员 

分 类 号：R575.2[医药卫生—消化系统]